The financial health and growth prospects of BNGO, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Similarly, Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
How much will BNGO go up? Stock Price Forecast
The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +208.29% increase from the last price of 2.60.
Thereof, Does ARKG hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Does BNGO have FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Is BNGO expected to rise?
Bionano Genomics Inc (NASDAQ:BNGO)
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +262.32% increase from the last price of 2.07.
Is BNGO a meme stock?
Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company.
Will BNGO get FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.94, with a high estimate of 86.57 and a low estimate of 24.08. The median estimate represents a +67.62% increase from the last price of 19.65.
What ETF holds BNGO?
ETF.com Insight
The largest ETF holder of BNGO is the iShares Russell 2000 ETF (IWM), with approximately 6.72M shares.
Is BNGO in ETF?
Bionano Genomics is a life sciences instrumentation company in the genome analysis space.
…
| ETF | BNGO |
|---|---|
| Shares Out. | 289.18M |
| Market Cap. | 615.96M |
| Div/Shr | 0.00 |
| Div Yield | 0.00 |
Is BNGO an ARKK?
Ark Invest’s Chapter in the BNGO Stock Story
The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material.
What is Saphyr system?
The Saphyr System automates optical genome mapping of ultra-high molecular weight DNA in its native state in proprietary NanoChannel arrays on the Saphyr Chip.
What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
What does BNGO company do?
Company Description
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
Does Cathie own BNGO?
Is Cathie Wood Invested in BNGO? As of the time of this writing, it does not appear that Cathie Wood or ARK are invested in Bionano Genomics. The firm’s genomics and biomedical ETF, ARKG, currently contains 52 individual holdings.
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
What institutions are buying BNGO?
Bionano Genomics (NASDAQ:BNGO) Institutional Buying and Selling
| Reporting Date | Hedge Fund | Ownership in Company |
|---|---|---|
| 2/14/2022 | Nuveen Asset Management LLC | 0.357% |
| 2/14/2022 | Barclays PLC | 0.123% |
| 2/14/2022 | GSA Capital Partners LLP | 0.019% |
| 2/14/2022 | Mutual Advisors LLC | 0.017% |
Does Ark hold BNGO?
Ark Invest’s Chapter in the BNGO Stock Story
The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material.
Why does Bionano have tremendous potential?
The Bottom Line on BNGO Stock
Saphyr allows diseases to be more effectively researched than competing products. And, it is tremendously cheaper than other genomic-mapping tools. But it could also more successfully determine patients more susceptible to severe cases of viruses. These viruses include Covid-19.
Join TheMoney.co community and don’t forget to share this post !
